Serum vascular adhesion protein-1 predicts all-cause mortality and cancer-related mortality in subjects with colorectal cancer

doi:10.1016/j.cca.2013.10.024

CNU IR > College of Sustainable Environment and Recreation > Dept. of Occupational Safety > Periodical Articles > Item 310902800/28694

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/28694

Title:	Serum vascular adhesion protein-1 predicts all-cause mortality and cancer-related mortality in subjects with colorectal cancer
Authors:	Li, Yu-I Hung, Ji-Shiang Yu, Tse-Ya Liou, Jyh-Ming Wei, Jung-Nan Kao, Hsien-Li Chuang, Lee-Ming Shun, Chia-Tung Lee, Po-Huang Lai, Hong-Shiee Su, Chien-Yin Li, Hung-Yuan Liang, Jin-Tung
Contributors:	職業安全衛生系
Keywords:	Vascular adhesion protein-1 Semicarbazide-sensitive amine oxidase Primary amine oxidase Mortality Colorectal cancer
Date:	2014-01
Issue Date:	2015-05-06 21:25:25 (UTC+8)
Publisher:	Elsevier Science Bv
Abstract:	Background: Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 can predict cancer mortality, including colorectal cancer (CRC) mortality, in type 2 diabetic subjects. However, it remains unknown if serum VAP-1 can predict mortality in CRC patients. This prospective cohort study investigates if serum VAP-1 is a novel biomarker for mortality prediction in CRC. Methods: We enrolled 300 CRC patients. Preoperative serum VAP-1 was measured by time-resolved immunofluorometric assay. They were followed until September 2009 or death, which was ascertained by the National Death Registration System. Results: The median follow-up period was 4.7 years. Compared with normal counterpart, VAP-1 immunoactivity was upregulated in CRC tissues, especially at the invasion front. Serum VAP-1 can independently predict all-cause mortality (HR: 1.0026, 95% Cl: 1.0003-1.0050, P < 0.05) and cancer-related mortality (HR: 1.0026, 95% Cl: 1.0001-1.0050, P <0.05). A risk score composed of age, gender, carcinoembryonic antigen (CEA) >5 ng/ml, tumor grading, tumor staging, and serum VAP-1 could stratify CRC patients into low-, intermediate-, and high-risk subgroups, with a 5-year mortality rate of 10%, 34%, and 78%, respectively. Conclusions: Serum VAP-1 predicts mortality independently and improves risk stratification in CRC subjects. (C) 2013 Elsevier B.V. All rights reserved.
Relation:	Clinica Chimica Acta, v.428 n., pp.51-56
Appears in Collections:	[Dept. of Occupational Safety] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1663	View/Open

Loading...